Panelists discuss clinical decision-making in EGFR-mutated non-small cell lung cancer, focusing on how emerging data are shaping treatment selection, risk–benefit assessment, and sequencing across lines of therapy, including monotherapy versus combination strategies, key efficacy and safety considerations, biomarker testing such as MET alterations, the emerging role of TROP2-directed antibody–drug conjugates, and the impact of subcutaneous administration on treatment burden and patient experience, with the goal of providing practical, evidence-informed insights to support clinical decision-making.
In this opening segment, Dr. Sands invites the panel to outline the current treatment landscape for EGFR-mutated non-small cell lung cancer, with Dr. Wakelee and Dr. Cooper highlighting how recent advances, including data from key phase III trials, are shaping first-line decisions, balancing monotherapy and combination strategies, and integrating efficacy, CNS activity, and tolerability into real-world clinical practice.
In this segment, Dr. Sands invites Dr. Cooper to explain how she evaluates key efficacy outcomes in selecting first-line therapy for EGFR-mutated non-small cell lung cancer, emphasizing the importance of integrating progression-free survival, overall survival, CNS activity, and patient-specific factors to guide individualized, real-world treatment decisions.
In this segment, Dr. Sands leads a discussion on how clinicians approach risk–benefit assessment in EGFR-mutated non-small cell lung cancer as newer combination strategies become available.
In this segment, Dr. Sands invites the panel to discuss how subcutaneous administration may influence treatment experience in EGFR-mutated non-small cell lung cancer, referencing data from the PALOMA-3 trial.
In this segment, Dr. Sands asks the panel to reflect on how emerging data presented at recent meetings, including ELCC, are influencing treatment strategies in EGFR-mutated non-small cell lung cancer.
In this segment, Dr. Sands asks Dr. Cooper to discuss the evolving role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Cooper explains that these agents are designed to deliver cytotoxic payloads directly to tumor cells by targeting TROP2, a surface antigen expressed in many epithelial cancers, thereby enhancing antitumor activity while attempting to limit off-target effects.
In this segment, Dr. Sands asks Dr. Wakelee to discuss the role of value-based frameworks in evaluating first-line treatment options for EGFR-mutated non-small cell lung cancer.
In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases
In this case-based segment, Dr. Sands presents a patient scenario involving a 64-year-old never-smoker with EGFR-mutated metastatic non-small cell lung cancer and asymptomatic brain metastases.
In this segment, Dr. Sands asks Dr. Cooper to discuss the role of intracranial efficacy in guiding first-line treatment decisions for EGFR-mutated non-small cell lung cancer.
In this segment, Dr. Sands asks Dr. Wakelee how she discusses toxicity profiles and treatment burden with patients when selecting first-line therapy for EGFR-mutated non-small cell lung cancer.
In this case-based segment, Dr. Sands presents a patient with EGFR-mutated metastatic non-small cell lung cancer who has progressed after first-line combination therapy with an EGFR tyrosine kinase inhibitor and chemotherapy, now with new brain metastases.
In this segment, Dr. Sands asks Dr. Wakelee to discuss how emerging data on MET-driven resistance mechanisms are shaping second-line treatment decisions in EGFR-mutated non-small cell lung cancer.
In this segment, Dr. Sands asks the panel to discuss the emerging role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Wakelee and Dr. Cooper explain that these agents are designed to target the TROP2 antigen on tumor cells and deliver a cytotoxic payload, enabling selective tumor cell killing.
In this final segment, Dr. Sands asks Dr. Cooper to discuss how subcutaneous administration of targeted therapies may influence clinical practice in EGFR-mutated non-small cell lung cancer.
